JADENU SPRINKLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for JADENU SPRINKLE (JADENU SPRINKLE).
Deferasirox is an oral iron chelator that selectively binds iron (Fe3+) with high affinity, forming a stable complex that is excreted primarily in the feces. It reduces iron overload by promoting iron excretion.
| Metabolism | Deferasirox is primarily metabolized via glucuronidation by UGT1A1 and UGT1A3, with minor involvement of CYP450 enzymes. It undergoes enterohepatic recirculation. |
| Excretion | Primarily fecal (84% of absorbed dose); renal excretion accounts for approximately 8% of total clearance. |
| Half-life | 8–28 hours (mean 11–19 hours); prolonged half-life correlates with iron overload and may require dose adjustments. |
| Protein binding | 99% bound to serum albumin. |
| Volume of Distribution | Approximately 1.0 L/kg; extensive distribution into tissues including liver and heart (primary iron storage sites). |
| Bioavailability | Oral: approximately 70% under fasting conditions; food reduces absorption by 25–30%. |
| Onset of Action | Oral: serum ferritin reduction noted within 2–4 weeks; maximal urinary iron excretion observed 4–6 hours post-dose. |
| Duration of Action | Urinary iron excretion persists for 24 hours; continuous daily dosing required to maintain chelation. |
Oral: Initial 20 mg/kg/day (max 30 mg/kg/day) administered once daily; titrate based on serum ferritin. For patients >14 years with serum ferritin >1000 mcg/L, use 20 mg/kg/day. Sprinkle capsules can be opened and contents sprinkled on soft food.
| Dosage form | GRANULE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not recommended in severe renal impairment (CrCl <40 mL/min) due to risk of accumulation. |
| Liver impairment | No specific dose adjustment defined; use with caution in Child-Pugh B or C due to limited data. |
| Pediatric use | Children ≥2 years: Initial 20 mg/kg/day (max 30 mg/kg/day) once daily; adjust based on serum ferritin. Not recommended for children <2 years. |
| Geriatric use | No specific dose adjustment; start at lower end of dosing range (20 mg/kg/day) due to potential for decreased renal function and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for JADENU SPRINKLE (JADENU SPRINKLE).
| Breastfeeding | It is not known whether deferasirox is excreted in human milk. In animal studies, deferasirox was detected in milk of lactating rats. The M/P ratio in humans is unknown. Due to potential for serious adverse reactions in nursing infants (e.g., gastrointestinal hemorrhage, cytopenias), breastfeeding should be discontinued during therapy or the drug should be avoided. |
| Teratogenic Risk | Deferasirox (JADENU SPRINKLE) is FDA Pregnancy Category C. In animal studies, deferasirox caused fetal toxicity (reduced fetal weight, increased skeletal variations) at maternal toxic doses. There are no adequate and well-controlled studies in pregnant women. First trimester: Potential risk of fetal harm based on animal data; avoid use unless benefit outweighs risk. Second and third trimesters: Limited data; consider risk of maternal iron overload vs. potential fetal effects. Use only if clearly needed. |
■ FDA Black Box Warning
WARNING: RENAL FAILURE, HEPATIC TOXICITY, AND GASTROINTESTINAL HEMORRHAGE. Acute renal failure, including fatalities, has been reported. Elderly patients, those with comorbidities such as renal impairment, or those taking medications that affect renal function are at increased risk. Hepatic toxicity, including fatal events, has occurred. Gastrointestinal hemorrhage, including fatal events, has been reported, especially in patients with advanced age or those with underlying GI conditions.
| Serious Effects |
["Hypersensitivity to deferasirox or any component of the formulation.","Severe renal impairment (eGFR < 15 mL/min/1.73 m²) or acute renal failure.","High-risk myelodysplastic syndrome (MDS) or advanced malignancies.","Platelet count < 50,000/mm³."]
| Precautions | ["Monitor serum creatinine and creatinine clearance at baseline and at least monthly thereafter. Reduce dose or interrupt therapy for renal impairment.","Monitor liver function tests (ALT, AST, bilirubin) at baseline and at least monthly. Interrupt therapy for severe or persistent elevations.","Assess for gastrointestinal hemorrhage, especially in elderly patients or those with prior GI ulcers or bleeding. Monitor for signs of GI bleeding.","Auditory and ophthalmic toxicity: Perform auditory and ophthalmic examinations at baseline and annually.","Monitor serum ferritin levels periodically to assess response to therapy.","Use caution in combination with other drugs that may increase the risk of renal or hepatic injury."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal complete blood count (CBC), serum ferritin, liver function tests (LFTs), serum creatinine, and urinalysis regularly. Monitor for gastrointestinal bleeding, rash, and auditory/ocular toxicity. Fetal monitoring: Ultrasound to assess growth and development if exposure occurs during pregnancy. |
| Fertility Effects | In animal studies, deferasirox did not impair fertility at clinically relevant doses. In males, no effects on spermatogenesis were observed. In females, no effects on estrous cycle or conception were noted. Human data are limited; however, no significant fertility impairment is expected based on current evidence. |